Milan S Geybels1, Bas A J Verhage, Frederik J van Schooten, R Alexandra Goldbohm, Piet A van den Brandt. 1. Affiliations of authors: Department of Epidemiology, GROW School for Oncology and Developmental Biology, (MSG, BAJV, PAvdB) and Department of Toxicology, NUTRIM School for Nutrition, Toxicology, and Metabolism (FJvS), Maastricht University, Maastricht, the Netherlands; TNO, Leiden, the Netherlands (RAG).
Abstract
BACKGROUND: Selenium may prevent advanced prostate cancer (PCa), but most studies on this topic were conducted in populations with moderate to high selenium status. We investigated the association of toenail selenium, reflecting long-term selenium exposure, and advanced PCa risk in a population from the Netherlands where low selenium status is widespread. METHODS: The analysis was conducted in the prospective Netherlands Cohort Study, which included 58 279 men aged 55 to 69 years at baseline in 1986. All cohort members completed a baseline questionnaire, and approximately 79% of participants provided toenail clippings, which were used for toenail selenium measurements using instrumental neutron activation analysis. Incident advanced PCa case subjects from the entire cohort were identified during 17.3 years of follow-up. The study employed a case-cohort design for which a random subcohort was sampled at baseline. Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. All tests were two-sided. RESULTS: Complete toenail selenium data were available for 898 advanced (International Union Against Cancer stage III/IV) PCa case subjects and 1176 subcohort members. The average toenail selenium concentration of subcohort members was 0.550 µg/g. Toenail selenium was associated with a reduced risk of advanced PCa; adjusted hazard ratio for the highest vs lowest quintile was 0.37 (95% CI = 0.27 to 0.51; P trend < .001). For stage IV PCa, men in the highest vs lowest quintile of toenail selenium had an adjusted hazard ratio of 0.30 (95% CI = 0.21 to 0.45; P trend < .001). CONCLUSIONS: Toenail selenium was associated with a substantial decrease in risk of advanced PCa.
BACKGROUND:Selenium may prevent advanced prostate cancer (PCa), but most studies on this topic were conducted in populations with moderate to high selenium status. We investigated the association of toenail selenium, reflecting long-term selenium exposure, and advanced PCa risk in a population from the Netherlands where low selenium status is widespread. METHODS: The analysis was conducted in the prospective Netherlands Cohort Study, which included 58 279 men aged 55 to 69 years at baseline in 1986. All cohort members completed a baseline questionnaire, and approximately 79% of participants provided toenail clippings, which were used for toenail selenium measurements using instrumental neutron activation analysis. Incident advanced PCa case subjects from the entire cohort were identified during 17.3 years of follow-up. The study employed a case-cohort design for which a random subcohort was sampled at baseline. Hazard ratios and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models. All tests were two-sided. RESULTS: Complete toenail selenium data were available for 898 advanced (International Union Against Cancer stage III/IV) PCa case subjects and 1176 subcohort members. The average toenail selenium concentration of subcohort members was 0.550 µg/g. Toenail selenium was associated with a reduced risk of advanced PCa; adjusted hazard ratio for the highest vs lowest quintile was 0.37 (95% CI = 0.27 to 0.51; P trend < .001). For stage IV PCa, men in the highest vs lowest quintile of toenail selenium had an adjusted hazard ratio of 0.30 (95% CI = 0.21 to 0.45; P trend < .001). CONCLUSIONS: Toenail selenium was associated with a substantial decrease in risk of advanced PCa.
Authors: Alan R Kristal; Amy K Darke; J Steven Morris; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; Frank L Meyskens; Gary E Goodman; Lori M Minasian; Howard L Parnes; Scott M Lippman; Eric A Klein Journal: J Natl Cancer Inst Date: 2014-02-22 Impact factor: 13.506
Authors: Stacey A Kenfield; Erin L Van Blarigan; Natalie DuPre; Meir J Stampfer; Edward L Giovannucci; June M Chan Journal: J Natl Cancer Inst Date: 2014-12-12 Impact factor: 13.506
Authors: John P Richie; Arun Das; Ana M Calcagnotto; Raghu Sinha; Wanda Neidig; Jiangang Liao; Eugene J Lengerich; Arthur Berg; Terryl J Hartman; Amy Ciccarella; Aaron Baker; Matthew G Kaag; Susan Goodin; Robert S DiPaola; Karam El-Bayoumy Journal: Cancer Prev Res (Phila) Date: 2014-06-17
Authors: A M J Gilsing; M P Weijenberg; R A Goldbohm; P C Dagnelie; P A van den Brandt; L J Schouten Journal: Eur J Clin Nutr Date: 2016-03-02 Impact factor: 4.016
Authors: Gagan Chhabra; Chandra K Singh; Mary Ann Ndiaye; Samantha Fedorowicz; Arielle Molot; Nihal Ahmad Journal: Cancer Lett Date: 2018-02-20 Impact factor: 8.679
Authors: Vanessa Er; J Athene Lane; Richard M Martin; Pauline Emmett; Rebecca Gilbert; Kerry N L Avery; Eleanor Walsh; Jenny L Donovan; David E Neal; Freddie C Hamdy; Mona Jeffreys Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-13 Impact factor: 4.254